AEZS - エテルナ・ゼンタリス (AEterna Zentaris Inc.) エテルナ・ゼンタリス

 AEZSのチャート


 AEZSの企業情報

symbol AEZS
会社名 AEterna Zentaris Inc (エテルナ・ゼンタリス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 エテルナ・ゼンタリス(AEterna Zentaris Inc.)は腫瘍と内分泌療法を専門にする医薬品開発企業。同社の製品パイプラインは創薬から市販製品までの開発のすべての段階における化合物を含む。腫瘍における優先順位は多発性骨髄腫に対するペリホシンを投与したフェーズ3プログラムと転移性大腸癌を含む多発性癌に対するフェーズ2プログラム、並びに進行性子宮内膜癌と進行性卵巣癌に対するAEZS-108を投与したフェーズ2プログラム、また他の癌適応症における潜在的な発展を含む。内分泌では同社のプログラムは成人成長ホルモン分泌不全症(AGHD)の診断のための成長ホルモン(GH) 刺激試験とするAEZS-130(SolorelTM)を投与したフェーズ3相試験の再活性化である。   エテルナ・ゼンタリスはカナダのバイオ医薬品メ―カ―。腫瘍及び内分泌疾患の治療法の開発、商業化に従事。パイプラインは、薬品の発見から開発、製品の販売までが含まれる。製品候補には、小児充実性腫瘍、子宮内膜がん、卵巣がん、前立腺がん、がん悪液質などの新治療薬がある。本社はカナダケベック州。   
本社所在地 1405 du Parc-Technologique Blvd. Quebec City Quebec G1P 4P5 CAN
代表者氏名 Carolyn Egbert キャロリン・エグベルト
代表者役職名 Independent Chairman of the Board
電話番号 +1 843-900-3223
設立年月日 33117
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 56人
url www.aezsinc.com
nasdaq_url https://www.nasdaq.com/symbol/aezs
adr_tso
EBITDA EBITDA(百万ドル) 5.17900
終値(lastsale) 1.67
時価総額(marketcap) 27456069.2
時価総額 時価総額(百万ドル) 28.28272
売上高 売上高(百万ドル) 25.24500
企業価値(EV) 企業価値(EV)(百万ドル) 8.33672
当期純利益 当期純利益(百万ドル) 1.70700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 AEterna Zentaris Inc. (USA) revenues increased from $504K to $24.8M. Net income totaled $11.8M vs. loss of $6.7M. Revenues reflect Licensing revenue increase from $220K to $24.7M. Net Income reflects Research and development costs net of r decrease of 70% to $1.8M (expense) Selling expenses decrease of 29% to $2.1M (expense).

 AEZSのテクニカル分析


 AEZSのニュース

   Aeterna Zentaris to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference  2021/01/05 13:05:00 GlobeNewswire
CHARLESTON, S.C., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical…
   Aeterna Zentaris, Novo Nordisk amends macimorelin licensing pact (NASDAQ:AEZS)  2020/11/16 13:47:48 Seeking Alpha
Aeterna Zentaris (NASDAQ:AEZS) jumps 6% in premarket, on amendment of its existing license agreement with Novo Nordisk (NYSE:NVO) related to the developmen
   Aeterna Zentaris Reports Third Quarter 2020 Financial Results and Provides Business Update  2020/11/06 13:35:00 GlobeNewswire
– Pivotal Phase 3 safety and efficacy study AEZS-130-P02 (“Study P02”) expected to commence in Q1 2021 – Continue to advance discussions to secure a…
   The Daily Biotech Pulse: Aurinia Pulls The Plug On Dry Eye Disease Study, Karyopharm's Positive Readout, Emergency Use Authorization For OraSure  2020/11/03 12:38:06 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 2) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Immunovant Inc (NASDAQ: IMVT ) United Therapeutics Corporation (NASDAQ: UTHR ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Nov. 2) AEterna Zentaris Inc. (NASDAQ: AEZS ) Aikido Pharma Inc (NASDAQ: AIKI ) Artelo Biosciences Inc (NASDAQ: ARTL ) Avita Therapeutics Inc (NASDAQ: RCEL ) Benitec Biopharma Inc (NASDAQ: BNTC ) BioCardia Inc (NASDAQ: BCDA ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Catabasis Pharmaceuticals Inc (NASDAQ: CATB ) Celsion Corporation (NASDAQ: CLSN ) Codiak BioSciences Inc (NASDAQ: CDAK ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Entasis Therapeutics Holdings Inc (NASDAQ: ETTX ) FSD Pharma Inc (NASDAQ: HUGE ) Galecto Inc (NASDAQ: GLTO ) (went public Thursday) Hoth Therapeutics Inc (NASDAQ: HOTH ) Inhibrx Inc (NASDAQ: INBX ) Iterum Therapeutics PLC (NASDAQ: ITRM ) Jaguar Health Inc (NASDAQ: JAGX ) Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) Monopar Therapeutics Inc (NASDAQ: MNPR ) Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV ) Neovasc Inc (NASDAQ: NVCN ) Neurobo Pharmaceuticals Inc (NASDAQ: NRBO ) Orchard Therapeutics PLC – ADR (NASDAQ: ORTX ) (halted dosing in Strimvelis study after it was linked to the development of leukemia in a patient) Orphazyme A S ADR (NASDAQ: ORPH ) Pliant Therapeutics Inc (NASDAQ: PLRX ) RA Medical Systems Inc (NYSE: RMED ) Recro Pharma Inc (NASDAQ: REPH ) Rockwell Medical Inc (NASDAQ: RMTI ) Teligent Inc (NEW JERSEY) (NASDAQ: TLGT ) Titan Pharmaceuticals, Inc. common stock (NASDAQ: TTNP ) Stocks In Focus Aurinia Ends Dry Eye Disease Study Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) said topline results from its Phase 2/3 AUDREY clinical study evaluating voclosporin ophthalmic solution for the potential treatment of …
   The Daily Biotech Pulse: Marinus Epilepsy Study Meets Goal, Novavax Reaches Vaccine Manufacturing Deal, Outset Medical's IPO  2020/09/15 11:55:39 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) 10X Genomics Inc (NASDAQ: TXG ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Avenue Therapeutics Inc (NASDAQ: ATXI ) Avidity Biosciences Inc (NASDAQ: RNA ) BioLife Solutions Inc (NASDAQ: BLFS ) Denali Therapeutics Inc (NASDAQ: DNLI ) Guardant Health Inc (NASDAQ: GH ) Immunomedics, Inc. (NASDAQ: IMMU ) - announced a deal to be bought by Gilead Sciences, Inc. (NASDAQ: GILD ) for $21 billion Inspire Medical Systems Inc (NYSE: INSP ) Kintara Therapeutics Inc (NASDAQ: KTRA ) Kura Oncology Inc (NASDAQ: KURA ) Nurix Therapeutics Inc (NASDAQ: NRIX ) Pacific Biosciences of California Inc (NASDAQ: PACB ) (announced the appointment of Susan Kim as CFO, effective Sept. 28) Shockwave Medical Inc (NASDAQ: SWAV ) SI-Bone Inc (NASDAQ: SIBN ) Silk Road Medical Inc (NASDAQ: SILK ) Stoke Therapeutics Inc (NASDAQ: STOK ) Trillium Therapeutics Inc (NASDAQ: TRIL ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 14) Acorda Therapeutics Inc (NASDAQ: ACOR ) AEterna Zentaris Inc. (NASDAQ: AEZS ) BELLUS Health Inc (NASDAQ: BLU ) PainReform Ltd (NASDAQ: PRFX ) Predictive Oncology Inc (NASDAQ: POAI ) Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS ) Stocks In Focus Marinus Reports Positive Late-Stage Readout In Epilepsy Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) announced positive top-line results from its registrational Phase 3 clinical trial, dubbed Marigold, evaluating the use of oral ganaxolone in children and young adults with CDKL5 deficiency disorder, a rare, genetic epilepsy with refractory seizures.
   Aeterna Zentaris Reports Third Quarter 2020 Financial Results and Provides Business Update  2020/11/06 13:35:00 GlobeNewswire
– Pivotal Phase 3 safety and efficacy study AEZS-130-P02 (“Study P02”) expected to commence in Q1 2021 – Continue to advance discussions to secure a…
   The Daily Biotech Pulse: Aurinia Pulls The Plug On Dry Eye Disease Study, Karyopharm's Positive Readout, Emergency Use Authorization For OraSure  2020/11/03 12:38:06 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 2) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Immunovant Inc (NASDAQ: IMVT ) United Therapeutics Corporation (NASDAQ: UTHR ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Nov. 2) AEterna Zentaris Inc. (NASDAQ: AEZS ) Aikido Pharma Inc (NASDAQ: AIKI ) Artelo Biosciences Inc (NASDAQ: ARTL ) Avita Therapeutics Inc (NASDAQ: RCEL ) Benitec Biopharma Inc (NASDAQ: BNTC ) BioCardia Inc (NASDAQ: BCDA ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Catabasis Pharmaceuticals Inc (NASDAQ: CATB ) Celsion Corporation (NASDAQ: CLSN ) Codiak BioSciences Inc (NASDAQ: CDAK ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Entasis Therapeutics Holdings Inc (NASDAQ: ETTX ) FSD Pharma Inc (NASDAQ: HUGE ) Galecto Inc (NASDAQ: GLTO ) (went public Thursday) Hoth Therapeutics Inc (NASDAQ: HOTH ) Inhibrx Inc (NASDAQ: INBX ) Iterum Therapeutics PLC (NASDAQ: ITRM ) Jaguar Health Inc (NASDAQ: JAGX ) Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) Monopar Therapeutics Inc (NASDAQ: MNPR ) Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV ) Neovasc Inc (NASDAQ: NVCN ) Neurobo Pharmaceuticals Inc (NASDAQ: NRBO ) Orchard Therapeutics PLC – ADR (NASDAQ: ORTX ) (halted dosing in Strimvelis study after it was linked to the development of leukemia in a patient) Orphazyme A S ADR (NASDAQ: ORPH ) Pliant Therapeutics Inc (NASDAQ: PLRX ) RA Medical Systems Inc (NYSE: RMED ) Recro Pharma Inc (NASDAQ: REPH ) Rockwell Medical Inc (NASDAQ: RMTI ) Teligent Inc (NEW JERSEY) (NASDAQ: TLGT ) Titan Pharmaceuticals, Inc. common stock (NASDAQ: TTNP ) Stocks In Focus Aurinia Ends Dry Eye Disease Study Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) said topline results from its Phase 2/3 AUDREY clinical study evaluating voclosporin ophthalmic solution for the potential treatment of …
   The Daily Biotech Pulse: Marinus Epilepsy Study Meets Goal, Novavax Reaches Vaccine Manufacturing Deal, Outset Medical's IPO  2020/09/15 11:55:39 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) 10X Genomics Inc (NASDAQ: TXG ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Avenue Therapeutics Inc (NASDAQ: ATXI ) Avidity Biosciences Inc (NASDAQ: RNA ) BioLife Solutions Inc (NASDAQ: BLFS ) Denali Therapeutics Inc (NASDAQ: DNLI ) Guardant Health Inc (NASDAQ: GH ) Immunomedics, Inc. (NASDAQ: IMMU ) - announced a deal to be bought by Gilead Sciences, Inc. (NASDAQ: GILD ) for $21 billion Inspire Medical Systems Inc (NYSE: INSP ) Kintara Therapeutics Inc (NASDAQ: KTRA ) Kura Oncology Inc (NASDAQ: KURA ) Nurix Therapeutics Inc (NASDAQ: NRIX ) Pacific Biosciences of California Inc (NASDAQ: PACB ) (announced the appointment of Susan Kim as CFO, effective Sept. 28) Shockwave Medical Inc (NASDAQ: SWAV ) SI-Bone Inc (NASDAQ: SIBN ) Silk Road Medical Inc (NASDAQ: SILK ) Stoke Therapeutics Inc (NASDAQ: STOK ) Trillium Therapeutics Inc (NASDAQ: TRIL ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 14) Acorda Therapeutics Inc (NASDAQ: ACOR ) AEterna Zentaris Inc. (NASDAQ: AEZS ) BELLUS Health Inc (NASDAQ: BLU ) PainReform Ltd (NASDAQ: PRFX ) Predictive Oncology Inc (NASDAQ: POAI ) Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS ) Stocks In Focus Marinus Reports Positive Late-Stage Readout In Epilepsy Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) announced positive top-line results from its registrational Phase 3 clinical trial, dubbed Marigold, evaluating the use of oral ganaxolone in children and young adults with CDKL5 deficiency disorder, a rare, genetic epilepsy with refractory seizures.
   The Daily Biotech Pulse: AstraZeneca Pauses Coronavirus Vaccine Study, Trillium To Get $25M Pfizer Investment  2020/09/09 11:23:14 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Akouos Inc (NASDAQ: AKUS ) Albireo Pharma Inc (NASDAQ: ALB )(announced positive Phase 3 results for odevixibat in a liver disorder called progressive familial intrahepatic cholestasis) Castle Biosciences Inc (NASDAQ: CSTL ) Harmony Biosciences Holdings Inc (NASDAQ: HRMY ) Kura Oncology Inc (NASDAQ: KURA ) Merit Medical Systems, Inc. (NASDAQ: MMSI )(announced sale of manufacturing equipment and associated assets used in its hypotube manufacturing business) X T L Biopharmaceuticals Ltd (NASDAQ: XTLB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 8) ADiTx Therapeutics Inc (NASDAQ: ADTX ) AEterna Zentaris Inc. (NASDAQ: AEZS )(announced the presentation of data from pediatric study of macimorelin for childhood-onset growth hormone deficiency) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Ayala Pharmaceuticals Inc (NASDAQ: AYLA ) Burning Rock Biotech Ltd (NASDAQ: BNR ) Checkmate Pharmaceuticals Inc (NASDAQ: CMPI ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP )( reacted to a negative data readout) Immatics NV (NASDAQ: IMTX ) Kymera Therapeutics Inc (NASDAQ: KYMR ) Legend Biotech Corp (NASDAQ: LEGN ) Regulus Therapeutics Inc (NASDAQ: RGLS ) Royalty Pharma plc (NASDAQ: RPRX ) Second Sight Medical Products Inc (NASDAQ: EYES ) Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS ) Viveve Medical Inc (NASDAQ: VIVE ) Stocks In Focus AstraZeneca Halts Coronavirus Vaccine Study to Allow For Safety Review Following an Unexplained Illness AstraZeneca plc (NYSE: AZN ) shares are under pressure after the company said in a statement to STATNews it has voluntarily paused the study of the coronavirus vaccine candidate it is jointly developing with the Oxford University in order to allow review of safety data by an independent committee.
   Aeterna Zentaris Reports Second Quarter 2020 Financial Results and Provides Business Update  2020/08/06 12:35:00 GlobeNewswire
– Positive results from AEZS-130-P01 (“Study P01”) confirmed dosing regimen of macimorelin as a potential diagnostic for childhood-onset growth hormone…
   Aeterna Zentaris Reports Second Quarter 2020 Financial Results and Provides Business Update  2020/08/06 12:35:00 GlobeNewswire
– Positive results from AEZS-130-P01 (“Study P01”) confirmed dosing regimen of macimorelin as a potential diagnostic for childhood-onset growth hormone…
   Aeterna Zentaris Announces Closing of $7.0 Million Registered Direct Offering Priced At-The-Market  2020/08/05 21:45:00 GlobeNewswire
CHARLESTON, S.C., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZS) (the “Company”), a specialty biopharmaceutical…
   AETERNA ZENTARIS ANNOUNCES $7.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET  2020/08/03 13:00:46 GlobeNewswire
CHARLESTON, S.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical…
   AETERNA ZENTARIS ANNOUNCES DISTRIBUTION AGREEMENT WITH MEGAPHARM LTD. TO COMMERCIALIZE MACIMORELIN IN ISRAEL AND THE PALESTINE AUTHORITY  2020/06/25 12:00:00 GlobeNewswire
CHARLESTON, S.C, June 25, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical…
   Aeterna Zentaris Reports First Quarter 2020 Financial and Operating Results  2020/05/06 12:05:00 GlobeNewswire
– First quarter marked by positive results from AEZS-130-P01 (“Study P01”), of macimorelin, providing clinical framework to advance pediatric investigation…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 エテルナ・ゼンタリス AEZS AEterna Zentaris Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)